Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia

Pediatric Blood and Cancer

Volumn 49, Issue 5, 2007, Pages 640-642

  Steiner, M ^a   Attarbaschi, A ^a   Kastner, U ^a   Dworzak, M ^a   Haas, O A ^a   Gadner, H ^a   Mann, G ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Ammonia; Asparaginase; Childhood leukemia; Monitoring

Indexed keywords

AMMONIA; ASPARAGINASE; CORTICOSTEROID; DAUNORUBICIN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMMONIA BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DRUG FORMULATION; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; HUMAN; LEUKEMIA; MALE; NEUROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG MONITORING; INFANT; PRESCHOOL CHILD;

ADOLESCENT; AMMONIA; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE;

EID: 35148867034     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21022     Document Type: Article

References (14)

1. Pratt CB, Roberts D, Shanks E, et al. Asparaginase in combination chemotherapy for remission induction of childhood acute lymphocytic leukemia. Cancer Res 1973;33:2020-2025.
2. van der Does-van den Berg A, Bartram CR, Basso G, et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM family" cooperative group. Med Pediatr Oncol 1992;20:497-505.
3. da Fonseca-Wollheim F. The significance of the hydrogen ion concentration and the addition of ADP in the determination of ammonia with glutamate dehydrogenase. An improved enzymic determination of ammonia. Z Klin Chem Klin Biochem 1973;11:421-425.
4. Leonard JV, Kay JD. Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet 1986;1:162-163.
5. Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of L-asparaginase in children with advanced leukemia. Cancer 1972;30:339-347.
6. Murthy CR, Rama Rao KV, Bai G, et al. Ammonia-induced production of free radicals in primary cultures of rat astrocytes. J Neurosci Res 2001;66:282-288.
7. Felipo V, Hermenegildo C, Montoliu C, et al. Neurotoxicity of ammonia and glutamate: Molecular mechanisms and prevention. Neurotoxicology 1998;19:675-681.
8. Cohn RM, Roth KS. Hyperammonemia, bane of the brain. Clin Pediatr (Phila) 2004;43:683-689.
9. Korinthenberg R, Scheuring B, Boos J, et al. On the origin of EEG-slowing and encephalopathy during induction treatment of acute lymphoblastic leukemia. Med Pediatr Oncol 2002;39:566-572.
10. Laterza OF, Gerhardt G, Sokoll LJ. Measurement of plasma ammonia is affected in patients receiving asparaginase therapy. Clin Chem 2003;49:1710-1711.
11. Muller HJ, Beier R, Loning L, et al. Pharmacokinetics of native escherichia coli asparaginase (asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001;114:794-799.
12. Zalewska-Szewczyk B, Andrzejewski W, Bodalski J. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2004;43:600-602.
13. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999;457:621-629.
14. Lanvers C, Vieira Pinheiro JP, Hempel G, et al. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem 2002;309:117-126.